Comparative Pharmacology
Head-to-head clinical analysis: DRONEDARONE versus PRONESTYL SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONEDARONE versus PRONESTYL SR.
DRONEDARONE vs PRONESTYL-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a multichannel blocker that inhibits potassium (IKr, IKs, IKur), sodium (INa), and calcium (ICaL) currents, and exhibits antiadrenergic effects via noncompetitive antagonism of beta-1 and beta-2 receptors. It also prolongs atrial refractoriness and slows atrioventricular conduction.
Class Ia antiarrhythmic agent; blocks sodium channels, slowing phase 0 depolarization and decreasing myocardial excitability; also prolongs refractory period and has anticholinergic effects.
400 mg orally twice daily after meals
500–1000 mg orally every 6 hours (sustained-release). Maximum 1.5 g per dose or 4 g per day.
None Documented
None Documented
Clinical Note
moderateDronedarone + Levofloxacin
"Dronedarone may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateDronedarone + Norfloxacin
"Dronedarone may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDronedarone + Gemifloxacin
"Dronedarone may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateDronedarone + Ibandronate
"Dronedarone may increase the QTc-prolonging activities of Ibandronate."
Terminal half-life is 13–19 hours; steady state achieved within 4–8 days.
2.5-4.7 hours (procainamide); 6-9 hours (NAPA, active metabolite). Prolonged in renal impairment (up to 11-20 hours for procainamide, 30-42 hours for NAPA).
Primarily fecal (≥84%) via biliary excretion; renal excretion accounts for <6% as unchanged drug.
Renal excretion: ~50-60% unchanged drug (procainamide), ~15-30% as N-acetylprocainamide (NAPA). Biliary/fecal: minor (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic